Recent advances have resulted in highly effective "tissue-agnostic" drugs that treat cancers based on their molecular markers ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...